Search results for "Isocitrate dehydrogenase"

showing 10 items of 16 documents

Concept of Spectrobiopsy Facing Gliomas: Rational and Future Perspectives Related to Target Therapy

2020

Gliomas represent the most common primary intracranial tumors with an estimated incidence of 31% of all central nervous system neoplasms. Lesions originated from glial cells are extremely heterogeneous, ranging from low grade to high grade with different clinical and biological malignancy. Glioblastoma multiforme (GBM) is the most aggressive and frequent primary malignant tumor of the central nervous system in adults. Even though in the past decades considerable efforts have been made in the therapeutic management of this type of tumor,2 the prognosis after diagnosis of GBM remains extremely poor, reaching a median overall survival of 12–18 months. In 2016 the World Health Organization clas…

2-Hydroxyglutaratemedicine.diagnostic_testbusiness.industryGlioma Humans Isocitrate Dehydrogenase Magnetic Resonance Imaging Magnetic Resonance SpectroscopyMagnetic resonance imagingmedicine.diseaseNuclear magnetic resonanceIsocitrate dehydrogenaseNeuroimagingGliomamedicineSurgeryNeurology (clinical)Target therapybusiness
researchProduct

Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma.

2019

Glioblastoma (GBM) is the most common malignant primary tumor of the central nervous system. With no effective therapy, the prognosis for patients is terrible poor. It is highly heterogeneous and EGFR amplification is its most frequent molecular alteration. In this light, we aimed to examine the genetic heterogeneity of GBM and to correlate it with the clinical characteristics of the patients. For that purpose, we analyzed the status of EGFR and the somatic copy number alterations (CNAs) of a set of tumor suppressor genes and oncogenes. Thus, we found GBMs with high level of EGFR amplification, low level and with no EGFR amplification. Highly amplified tumors showed histological features of…

0301 basic medicineMaleCancer ResearchBiopsyL-amp GB EGFR-low amplified glioblastomamedicine.disease_causewt wildtypeMYBPC3 myosin-binding protein C0302 clinical medicineHIC1 hypermethylated in cancer 1Gene duplicationIn Situ Hybridization FluorescenceIDH2 isocitrate dehydrogenase 2MutationRB-pat RB signaling pathwayEGFRvIII epidermal growth factor receptor variant number IIIPAH phenylalanine hydroxylaseGBM glioblastoma IDH-wildtype (glioblastoma multiforme primary glioblastoma).ANOVA ANalysis Of VArianceN-amp GB EGFR-no amplified glioblastomaMiddle AgedCDKN2A cyclin-dependent kinase inhibitor 2Alcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisPrimary tumorImmunohistochemistryH-amp GB EGFR-high amplified glioblastomaErbB ReceptorsTKR-pat tyrosine-kinase receptors signaling pathway030220 oncology & carcinogenesisDisease ProgressionCDK6 cyclin-dependent kinase 6CDH1 Cadherin 1FemaleCREM cAMP response element modulatorIHC immunohistochemistryAdultOriginal articleDNA Copy Number VariationsCDKN1B cyclin-dependent kinase inhibitor 1BBiologyRARB retinoic acid receptor betaCNS central nervous systemlcsh:RC254-282IDH1 isocitrate dehydrogenase 1BCL2 B-cell cll/ lymphoma 2CNAs copy number algerationsWHO World Health Organization03 medical and health sciencesYoung Adultp53-pat p53 signaling pathwaymedicineBiomarkers TumorTMA tissue microarrayPTENHumansProtein kinase BPI3K/AKT/mTOR pathwaySurvival analysisAgedGenetic heterogeneityGene AmplificationGFAP glial fibrillary acidic proteinMLPA multiplex ligation-dependent probe amplificationmedicine.diseaseFISH fluorescence in situ hibridizationSurvival AnalysisCDKN2B cyclin-dependent kinase inhibitor 2BPTEN phosphatase and tensin homologEGFR epidermal growth factor receptorCNV-load load of copy number variations030104 developmental biologyMutationPARK2 parkinCancer researchbiology.proteinTCGA The Cancer Genome AtlasLARGE1 acetylglucosaminyltransferase-like protein 1GlioblastomaCHD7 Chromodomain Helicase DNA Binding Protein 7DAPI 4′6-diamidino-2-phenylindoleNeoplasia (New York, N.Y.)
researchProduct

Assessing the genetic diversity ofCentaurea parlatorisgroup (sect.Dissectae, Compositae) in Sicily using isozymes

2011

Abstract The Centaurea parlatoris group belongs to sect. Dissectae and is one of the most taxonomically critical groups in Sicily. The taxa included in it inhabit dry slopes, pastures and rocky places. Some of them are narrow endemics to Sicily, and others to Italy. The great morphological variability at the intrapopulation level has not permitted the creation of an adequate taxonomic scheme. The recent proposal of two new species from Sicily confirms the insufficient knowledge of the taxonomic diversity. This study involves eight Sicilian populations of the C. parlatoris group. Seven loci from nine enzyme systems [isocitrate dehydrogenase (IDH), malate dehydrogenase (MDH), 6-phosphoglucona…

Genetic diversitybiologyPlant Sciencebiology.organism_classificationMalate dehydrogenaselanguage.human_languageIsocitrate dehydrogenaseTaxonCentaureaCentaurea endemics genetic diversity isozyme SicilyBotanylanguagePhosphoglucomutaseEndemismSicilianEcology Evolution Behavior and SystematicsPlant Biosystems - An International Journal Dealing with all Aspects of Plant Biology
researchProduct

Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advan…

2020

Aim To investigate multivariable analyses for noninvasive association of the isocitrate dehydrogenase (IDH) mutational status in grade II and III gliomas including evaluation of T2 mapping-sequences. Methods Magnetic resonance imaging (MRI) examinations with histopathologically proven World Health Organization grade II and III gliomas were retrospectively enrolled. Multivariate receiver operating characteristics (ROC) analyses to associate IDH mutational status were performed containing quantitative T2 mapping analyses and qualitative characteristics (sex, age, localization, heterogeneity, oedema, necrosis and diameter). Relaxation times were calculated pixelwise by means of standardized RO…

OncologyAdultMalemedicine.medical_specialtyT2 mappingWorld Health OrganizationWorld health030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineMagnetic resonance imaging T2 mappingGliomaInternal medicinemedicineMutational statusHumansRadiology Nuclear Medicine and imagingNeoplastic DiseasesAgedRetrospective StudiesAged 80 and overbusiness.industryBrain NeoplasmsNon invasiveGeneral MedicineGliomaMiddle Agedmedicine.diseasePrognosisMagnetic Resonance ImagingIsocitrate DehydrogenaseMRI - Magnetic resonance imagingIsocitrate dehydrogenaseMutationFemaleNeurology (clinical)Neoplasm Gradingbusiness030217 neurology & neurosurgery
researchProduct

T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma.

2021

Purpose To characterise peritumoral zones in glioblastoma and anaplastic astrocytoma evaluating T2 values using T2 mapping sequences. Materials and methods In this study, 41 patients with histopathologically confirmed World Health Organization high grade gliomas and preoperative magnetic resonance imaging examinations were retrospectively identified and enrolled. High grade gliomas were differentiated: (a) by grade, glioblastoma versus anaplastic astrocytoma; and (b) by isocitrate dehydrogenase mutational state, mutated versus wildtype. T2 map relaxation times were assessed from the tumour centre to peritumoral zones by means of a region of interest and calculated pixelwise by using a fit m…

Pathologymedicine.medical_specialtyT2 mappingmultiparametric imagingAstrocytoma03 medical and health sciencesT2 mapping0302 clinical medicineGliomagliomamedicineHumansRadiology Nuclear Medicine and imagingneoplasmsRetrospective Studiesbusiness.industryBrain NeoplasmsMRI (magnetic resonance imaging)General MedicineOriginal Articlesmedicine.diseaseMagnetic Resonance ImagingIsocitrate DehydrogenaseMRI - Magnetic resonance imagingnervous system diseases030220 oncology & carcinogenesisMutationNeurology (clinical)businessGlioblastomaInfiltration (medical)030217 neurology & neurosurgeryGlioblastomaAnaplastic astrocytomaThe neuroradiology journal
researchProduct

Analysis of the Cellular Roles of MOCS3 Identifies a MOCS3-Independent Localization of NFS1 at the Tips of the Centrosome

2019

The deficiency of the molybdenum cofactor (Moco) is an autosomal recessive disease, which leads to the loss of activity of all molybdoenzymes in humans with sulfite oxidase being the essential protein. Moco deficiency generally results in death in early childhood. Moco is a sulfur-containing cofactor synthesized in the cytosol with the sulfur being provided by a sulfur relay system composed of the L-cysteine desulfurase NFS1, MOCS3, and MOCS2A. Human MOCS3 is a dual-function protein that was shown to play an important role in Moco biosynthesis and in the mcm(5)s(2) U thio modifications of nucleosides in cytosolic tRNAs for Lys, Gln, and Glu. In this study, we constructed a homozygous MOCS3 …

inorganic chemicalsCoenzymesBiochemistry03 medical and health scienceschemistry.chemical_compoundRNA Transferddc:570Sulfite oxidaseMetalloproteinsHumansnatural sciencesInstitut für Biochemie und BiologieAconitate HydrataseCentrosome0303 health sciencesPteridinesSulfite Oxidase030302 biochemistry & molecular biologyNucleotidyltransferasesIsocitrate DehydrogenaseCell biologyCarbon-Sulfur LyasesHEK293 CellschemistryCentrosomeSulfurtransferasesbacteriaCRISPR-Cas SystemsMolybdenum cofactorMolybdenum CofactorsHeLa CellsBiochemistry
researchProduct

Magnetic Resonance Spectrobiopsy for Prediction of Isocitrate Dehydrogenase Mutation in Glioma

2020

Despite the existence of multimodal therapy paradigm, high-grade gliomas (HGGs) remain devastating tumors associated with one of the worst prognoses. Glioblastoma (GBM) is the most frequent reported histologic type with a median survival, after surgery and combined treatment with chemotherapy and radiotherapy, ranging from 12 to 16 months. The poor prognosis is due to the lack of therapeutic efficacy of chemical agents and irradiation in hypoxic tumor areas. Experimental studies have investigated several molecules with the aim to counteract several downstream signaling important in tumor progression, unfortunately without conclusive results. Several studies have shown that the extent of res…

2-Hydroxyglutaratemedicine.diagnostic_testbusiness.industryGlioma Humans Isocitrate Dehydrogenase Magnetic Resonance SpectroscopyMagnetic resonance imagingNuclear magnetic resonance spectroscopymedicine.diseaseIsocitrate dehydrogenaseNuclear magnetic resonanceNeuroimagingGliomaMutation (genetic algorithm)MedicineSurgeryNeurology (clinical)businessWorld Neurosurgery
researchProduct

Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique

2016

Abstract Patients with malignant gliomas have a poor prognosis with average survival of less than one year. Whereas in other tumor entities the characteristics of tumor metabolism are successfully used for therapeutic approaches, such developments are very rare in brain tumors, notably in gliomas. One metabolic feature characteristic of gliomas, in particular diffuse astrocytomas and oligodendroglial tumors, is the variable content of D-2-hydroxyglutarate (D2HG), a metabolite, which was discovered first in this tumor entity. D2HG is generated in large amounts due to various “gain-of–function” mutations in the isocitrate dehydrogenases IDH-1 and IDH-2. Meanwhile, D2HG has been detected in se…

0301 basic medicineCancer ResearchPathologymedicine.medical_specialtyMetabolite610 MedizinBiology03 medical and health scienceschemistry.chemical_compoundmedicineBioluminescence imagingBioluminescenceOligodendroglial TumorOriginal Researchddc:610D-2 hydroxyglutarateglioblastomaMyeloid leukemiaCancerACUTE MYELOID-LEUKEMIA; ISOCITRATE DEHYDROGENASE 1; IDH2 MUTATIONS; CHROMATOGRAPHY/MASS SPECTROMETRY; MAGNETIC-RESONANCE; 2-HYDROXYGLUTARATE; CANCER; GLIOMAS; L-2-HYDROXYGLUTARATE; METABOLITES; D-2 hydroxyglutarate; IDH mutations; bioluminescence imaging; oncometabolite; glioblastomabioluminescence imagingIDH mutationsmedicine.diseaseoncometaboliteLymphoma030104 developmental biologychemistryOncologyChondrosarcoma
researchProduct

Effects of training on regional substrate oxidation in the hearts of ageing rats.

1989

23-month-old male rats were trained by running for 20 weeks. The oxidation rates of succinate, glutamate+malate, palmitoylcarnitine, and pyruvate and the activities of lactate dehydrogenase, citrate synthase, isocitrate dehydrogenase and cytochrome oxidase were measured in the subendocardium and subepicardium and in the right ventricle. Regional differences of substrate oxidation rates in the myocardium of old sedentary or trained rats were less than in young rats, suggesting that regional differences in the cardiac work load disappear during ageing. Training did not improve oxidation rates, in contradiction to some previous results.

Malemedicine.medical_specialtyAgingCitrate (si)-SynthaseElectron Transport Complex IVchemistry.chemical_compoundLactate dehydrogenaseInternal medicinePhysical Conditioning AnimalmedicineCitrate synthaseCytochrome c oxidaseAnimalsPalmitoylcarnitinebiologyL-Lactate DehydrogenaseMyocardiumBody WeightGlutamate receptorHeartRats Inbred StrainsOrgan SizeIsocitrate DehydrogenaseRatsmedicine.anatomical_structureIsocitrate dehydrogenaseEndocrinologychemistryAgeingVentriclebiology.proteinGeriatrics and GerontologyOxidation-Reduction
researchProduct

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker…

2017

Abstract Background Combination chemotherapy has shown benefit in the treatment of biliary cancer and further improvements might be achieved by the addition of a biological agent. We report here the effect of chemotherapy with the monoclonal EGFR antibody panitumumab as therapy for KRAS wild-type biliary cancer. Patients and methods Patients with advanced biliary tract cancer were randomised (2:1) to receive cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 on day 1 and day 8/q3w with (arm A) or without panitumumab (arm B; 9 mg/kg BW, i.v q3w). The primary end-point was the evaluation of progression-free survival (PFS) at 6 months. Secondary end-points included objective response rate (ORR), ov…

MaleOncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinKaplan-Meier Estimatemedicine.disease_causeDeoxycytidine0302 clinical medicineRisk FactorsGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicinePrecision MedicineAged 80 and overPanitumumabAntibodies MonoclonalCombination chemotherapyMiddle AgedIsocitrate DehydrogenaseBiliary Tract NeoplasmsTreatment OutcomeOncology030220 oncology & carcinogenesisDisease ProgressionBiomarker (medicine)Female030211 gastroenterology & hepatologyKRASmedicine.drugAdultmedicine.medical_specialtyAdolescentDisease-Free SurvivalProto-Oncogene Proteins p21(ras)Young Adult03 medical and health sciencesInternal medicineBiomarkers TumorHumansPanitumumabAgedCisplatinChemotherapybusiness.industryGene Expression ProfilingGemcitabineGemcitabineClinical trialMutationCisplatinbusinessEuropean Journal of Cancer
researchProduct